RESULTS OF NEW RESEARCH

Warner House, Inc. A Center for the Study and Treatment of Down Syndrome        


 Amyloid-B Level Testing in Young Adults with Down Syndrome on Long-Term Antioxidant Treatment 

Study design and development by Beverly Sommer, President and CEO


A study to quantify blood plasma amyloid beta levels (an indicator of Alzheimer disease (AD) with clients of Warner House, Inc. who have been taking the proprietary metabolic formula HAP Caps designed by Dr. Warner to combat the deteriorating symptoms of Down Syndrome (DS). P-tau, another indicator of AD has also been measured.

Investigative research has detected a marked reduction in the enzyme catalase in people with DS. Without the proper amount of catalase, the conversion of superoxide dismutase (SOD) will not transfer into the next oxidative state. The deficiency results in an accumulation of SOD in each cell of the body in DS. Formulated to reduce levels of SOD, HAP Caps also aid cellular defenses with the use of antioxidants, vitamins, minerals, amino acids and enzymes.
Results of the earlier studies of patients taking HAP Caps show increased height and musculature; more normalized facial features; improved cognition. 

Although Alzheimer's Disease (AD) affects about 1 in 10 people over the age of 65, it is found in a substantially greater percentage in people with DS and at a much earlier age. AD and DS are both found on the 21st chromosome. It Is now possible to show a diagnosis (for research use only) of AD by measuring the amount of amyloid beta in the blood. Results of the study will show if amyloid beta levels in participants who take HAP Caps are significantly reduced compared to amyloid beta levels in the blood of people with DS who have not taken the formula. This is key in identifying HAP Caps as a prevention or delay of onset of AD symptoms. This could have a profound impact both in people with Down Syndrome as well as the general population. 

A ratio of amyloid beta 42 compared to levels of amyloid beta 40 has shown an average ratio of 0.0390.  The higher the ratio the higher the risk of AD. The ratio of Warner patients is significantly lower than people with Down syndrome, age-related who have not taken HAP Caps by more than 0.05 (5%). Five percent is the level of improvement assigned by research scientists to indicate a significant difference. 

An average of P-tau results was shown to be 3.62, significantly lower than people who have not taken HAP Caps. However, P-tau is thought to become more relevant as individuals age. Ages of Warner clients at time of study (May 2024) were between 20 - 40. We would learn much more if the study can be repeated in the future.    

We would like to thank participants of the study and their families for their commitment to taking HAP Caps as well
as their interest in furthering scientific knowledge of AD in the Down syndrome community. 

There are many ways to get involved with Warner House. Attend one of our events, become a member, or volunteer your time. We'd love to have you on board!

From providing education to supporting health care initiatives, Warner House offers a range of programs to support communities in need. Learn more about our work.